On Sunday afternoon, I attended the Continuing Education course titled “Detecting Cancer Risk in Drugs: Design, Conduct, and Interpretation of Carcinogenicity Studies for Regulatory Approvals.” Dr. McMaster opened the course with an overview of current procedures of carcinogenicity testing of drugs.
Have you ever wondered how safety evaluation for the inhalation route could be performed without the use of animals and how to leverage in vitro data to do so?
While the use of read-across and other techniques based on chemical structure to understand toxicological hazard have been used for several decades, expanded interest in using such techniques to minimize in vivo testing coupled with NAM advances has led to new advances.
The intention of this SOT CE course is to highlight the development and application of novel methods and approaches that have the potential to improve well-established safety studies and risk assessments.
Reproductive safety issues are a more common occurrence in drug development than you might expect. When these come along it’s not always easy to determine where to start or if there is even a path forward.